Primary cardiac sarcoma: demographics, genomic study correlation, and survival benefits of surgery with adjuvant therapy in U.S. population

Background Cardiac sarcomas are rare and aggressive tumors with little known about the demographics, genetics, or treatment outcomes. Objectives The objectives of this study were to characterize the demographics, treatment modality, and survival associated with cardiac sarcomas and evaluate the pote...

Full description

Saved in:
Bibliographic Details
Published in:Clinical research in cardiology 2024-05, Vol.113 (5), p.694-705
Main Authors: Khan, Rozi, Sunthankar, Kathryn I., Yasinzai, Abdul Qahar Khan, Tareen, Bisma, Zarak, Muhammad Samsoor, Khan, Jaffar, Nasir, Hassan, Nakasaki, Manando, Jahangir, Eiman, Heneidi, Saleh, Ullah, Asad
Format: Article
Language:English
Subjects:
Cardiology
Chemotherapy
Demographics
Demography
Genetics
Genomics
Heart diseases
Medicine
Medicine & Public Health
Metastases
Next-generation sequencing
Original Paper
Patients
Sarcoma
Surgery
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Cardiac sarcomas are rare and aggressive tumors with little known about the demographics, genetics, or treatment outcomes. Objectives The objectives of this study were to characterize the demographics, treatment modality, and survival associated with cardiac sarcomas and evaluate the potential for mutation-directed therapies. Methods All cases from 2000 to 2018 of cardiac sarcoma were extracted from the SEER database. Genomic comparison utilized The Cancer Genome Atlas (TCGA) database, as well as reviews and re-analysis of past applicable genomic studies. Results Cardiac sarcomas occurred most often in White patients, compared with national census data cardiac sarcomas occurred at a significantly higher rate in Asians. The majority of cases were undifferentiated (61.7%) and without distant metastases (71%). Surgery was the most common primary treatment modality and offered survival benefit (HR 0.391 ( p  = 0.001) that was most pronounced and sustained as compared to patients who received chemotherapy (HR 0.423 ( p  = 0.001) or radiation (HR 0.826 ( p  = 0.241) monotherapy. There was no difference in survival when stratified by race or sex; however, younger patients (
ISSN:1861-0684
1861-0692
DOI:10.1007/s00392-023-02236-x